Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
A. Snyder,V. Makarov,18 Authors,T. Chan
2014 · DOI: 10.1056/NEJMoa1406498
New England Journal of Medicine · 3,863 Citations
TLDR
These findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti-CTLA- 4 agents are being considered.